ABBV vs GOOG: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Alphabet Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Alphabet Inc. · Communication Services
$339.40
-6.2% upside to fair value
Grade D
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
GOOG trades at a lower forward P/E
(31.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GOOG |
| Current Price |
$197.69 |
$339.40 |
| Fair Value Estimate |
$210.22 |
$318.47 |
| Upside to Fair Value |
+6.3%
|
-6.2%
|
| Market Cap |
$349.7B |
$4,105.7B |
| Forward P/E |
83.3x
|
31.2x
|
| EV / EBITDA |
23.4x
|
23.1x
|
| Price / Sales |
5.7x
|
10.3x
|
| Price / FCF |
18.7x
|
56.4x
|
| Revenue Growth YoY |
+10.0%
|
+11.3%
|
| Gross Margin |
70.2%
|
59.7%
|
| Operating Margin |
26.7%
|
32.0%
|
| Return on Equity |
-361.6%
|
35.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
1.77%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Alphabet Inc. operates as a global leader in internet content, advertising, cloud computing, and AI technologies, with dominant market positions in search, browser, and mobile operating systems. The company benefits from a high-quality business model characterized by a durable competitive moat, strong revenue growth of 11.3% year-over-year, and robust profitability with net margins of 32.8%. Desp…
Accumulation Zones
| Metric |
ABBV |
GOOG |
| Zone Low |
$157.66 |
$238.85 |
| Zone High |
$178.69 |
$270.70 |
| In Buy Zone? |
No
|
No
|